The immunosuppressive drug mycophenolic acid (MPA) is a potent and specific inhibitor of IMP dehydrogenase, the first committed step of GMP synthesis. A screen for yeast genes affecting MPA sensitivity, when overexpressed, allowed us to identify two genes, IMD2 and TPO1, encoding an homologue of IMP dehydrogenase and a vacuolar pump, respectively. In parallel, 4787 yeast strains, each carrying an identified knock-out mutation, were tested for growth in the presence of MPA, allowing identification of 100 new genes affecting MPA resistance when disrupted. Disturbance of several cellular processes, such as ergosterol biosynthesis, vacuole biogenesis or glycosylation impaired the natural capacity of yeast to resist MPA, although most of the highly sensitive mutants affected the transcription machinery (19 mutants). Expression of TPO1 and/or IMD2 was strongly affected in 16 such transcription mutants suggesting that low expression of these genes could contribute to MPA sensitivity. Interestingly, the spt3, spt8 and spt20 mutants behaved differently to other SAGA mutants.
RESULTS and DISCUSSION
Overexpression of IMD2 and TPO1 result in increased resistance to MPA. As a first step toward identification of genes affecting resistance to MPA, a yeast wild-type strain (Y350) was transformed with a genomic library in the multicopy YEp13 vector (12) and directly plated on SC medium containing MPA (100 mg/l). Plasmids from three yeast MPA resistant transformants were purified in E.
coli and shown to confer MPA resistance when retransformed in yeast. Sequence of the plasmid inserts revealed that they all contained a fragment of chromosome VIII carrying the IMD2 gene encoding an isoform of IMP dehydrogenase (IMPDH), the enzyme inhibited by MPA. One of these plasmids (P1736) was further studied and overexpression of IMD2 was shown to be responsible for MPA resistance by subcloning experiments (Fig 1A) . Since this overexpression screen allowed identification of a single gene, a second experiment was carried out with a different genomic library to increase the overall representativity of the screen. The wild-type BY4742 strain transformed with a multicopy library, constructed in the PFL44L vector (URA3, 2µm), allowed isolation of two plasmids clearly conferring MPA resistance. Both plasmids contained a fragment of chromosome XII, and further subcloning experiments revealed that the previously characterized TPO1 gene (13) was responsible for MPA resistance (Fig. 1B) . This gene encodes a multidrug-resistance protein of the major facilitator superfamily (14), recently characterized as a vacuolar membrane protein involved in polyamine transport (13). Homologs of both IMD2 and TPO1 have been shown to affect MPA resistance in other yeast species. Indeed, overexpression of Candida albicans IMPDH leads to MPA resistance (15) while knock-out of FLU1, encoding a protein highly similar to Tpo1p, makes C. albicans more sensitive to MPA (16). Similarly, a S. cerevisiae tpo1 mutant strain was slightly more sensitive to MPA than the wild-type strain (data not shown). We also found that concomitant overexpression of IMD2 and TPO1
did not lead to additive resistance to MPA (Fig. 1C) .
We then intended to determine whether overexpression of IMD3 and IMD4 encoding the two mutants displaying severe growth defects even in the absence of the drug.
To verify that the MPA phenotype was indeed due to the knock-out mutation and not to an unlinked mutation, complementation of the MPA phenotype by the cognate wild-type gene carried on a plasmid was shown for 32 mutants (marked by an asterisk in Table 1 , data not shown). For all the other mutants, we verified by PCR that the knock-out was indeed at the expected locus (data not shown).
Although multiple aspects of yeast biology appear critical for growth in the presence of MPA, the most obvious functional group of mutants affected transcription. This group was not only the largest one, but it also contained the most sensitive mutants. Four of these mutants, dst1, rtf1, rpb9 and paf1 were previously known to be sensitive to 6AU and MPA (3, (5) (6) (7) . Examples of growth phenotypes of such transcription mutants on MPA and 6AU are presented on Fig. 2 . Among those mutants, met18 led to increased resistance to both drugs. Met18p (Mms19p) is involved in transcription and DNA repair through TFIIH activity, although this effect appears indirect (19) . The reason for MPA resistance of the met18 mutant is not clear and could affect a yet uncharacterized function of this gene since none of the other mutants identified in this study are affected in DNA repair or TFIIH.
Specific SAGA mutants are highly sensitive to MPA. Among the most sensitive mutants are spt3, spt7, spt8 and spt20 mutants affecting the SAGA complex (Fig. 3A) . MPA sensitivity of these mutants was fully prevented by addition of guanine, thus establishing that the drug affected growth of these mutants strains through depletion of the guanylic nucleotide pools. This was further confirmed by showing that the spt mutants were also highly sensitive to 6AU (Fig. 3B) . Growth of the spt3 mutant was impaired at MPA doses as low as 0.5 mg/l and totally abolished at 5 mg/l (Fig. 3C) . Strikingly, mutants affecting other components of the SAGA, such as Gcn5p or Ada1/2/3p proteins, were not detected as MPA sensitive in the screen, although the cognate mutant strains were present in the knock-out collection.
Further investigation revealed that indeed ada2, ada3 and gcn5 were clearly not sensitive to the drug (Fig. 3D ), while ada1 was sensitive but was not selected due to a severe growth defect even in the 15/05/02 absence of MPA, as discussed in previous section (Fig. 3D ). This result indicates that only a subset of SAGA functions is affected by guanylic nucleotide limitation thus confirming that SAGA subcomplexe(s) could have separate functions (20) (21) (22) .
RNA polymerase mutants. Knock-out of the RPB4 and RPB9 genes, encoding non essential subunits of RNA Polymerase II, were clearly sensitive to MPA (Fig. 3A) and reversed by guanine. It was previously shown that a point mutation in RPB2 encoding an essential subunit of PolII results in MPA sensitivity (4) and recently a similar phenotype was reported for the rpb9 mutant (6). The drug effect was presumed to stress the transcriptional elongation machinery as the result of decreased nucleotide concentration. Indeed, the importance of nucleotides concentration on transcription elongation was recently demonstrated in E. coli, in which allosteric binding of NTPs to RNA polymerase was shown to regulate transcription elongation (23) . Surprisingly, rpb4 mutant appeared only slightly sensitive to 6AU while rpb9 mutant was not strongly affected by this drug (Fig. 3B ), in contradiction with previously published results (24) . This discrepancy could be due to differences in strain background resulting in some indirect effect on uptake or potentiation of 6AU, thus limiting its effect on the guanine nucleotide pool. Finally, we found that a mutation in the RPA49 gene encoding a RNA PolI subunit is sensitive to both 6AU and MPA, thus showing that these drugs are not specific of RNA PolII. (Fig. 4A) . The PDA1 transcript, used as loading control, was not significantly affected by MPA treatment in the wild-type strain (Fig. 4A) . In three mutants, htz1, met18 and rpa49, neither TPO1 nor IMD2 expression was strongly affected (Fig. 4A, 4B ) and their phenotype relative to MPA could therefore not be attributed to altered expression of IMD2 or TPO1. All the other mutant strains showed lower expression of TPO1 or/and IMD2 transcript in the presence of MPA : i. e. at least two folds lower than that of the wild-type strain (Fig 4A, 4B ). Mutants hpr1 and rtf1 were found specifically affected for IMD2 expression, while mutants snf2, snf6 and ctk1 were mostly affected for TPO1 expression. Finally, the remaining mutants spt3, spt7, spt8, spt20, mot3, dal81, ctk3, paf1, rpb4, rpb9 and dst1 were affected for expression of both genes (Fig 4A, 4B ).
Effect of the transcription
Importantly, in most of the mutants, expression of TPO1 and/or IMD2 transcript(s) was only affected in the presence of MPA (compare Fig. 4B and 4C). We interpret this observation as follows :
transcription of TPO1 and/or IMD2 is not strongly affected in these mutant strains unless guanylic nucleotide pool is diminished (in the presence of MPA). This is precisely the predicted behavior of transcription elongation mutants (25) . Indeed, among these mutants are those (dst1, rtf1, rpb9, hpr1, paf1, ctk1) that were directly or indirectly related to transcription elongation (5-7, 24, 27-28) . While this result suggests that several of these genes products could be involved in transcription elongation, we cannot rule out that some of these transcription factors could be specifically required for increased transcription initiation of TPO1 and/or IMD2 in cells with low GTP levels (in the presence of MPA).
Surprisingly, the SAGA mutants spt3, spt8 and spt20 clearly affected IMD2 expression only in the presence of MPA, thus indicating a possible role for some SAGA subunits in transcription elongation. However, this observation could not be generalized to all SAGA mutants, indeed the spt7 mutant showed very low expression of IMD2 and TPO1 both in the presence or absence of the drug 15/05/02 (Fig. 4A , B, C), while expression of these two genes was not significantly decreased in ada2, ada3 and gcn5 mutants (Fig. 4D) . Therefore, our results reveal a good correlation between TPO1 and IMD2 expression levels in the SAGA mutants and their respective sensitivity to MPA (Fig. 3D ).
We found that overexpression of TPO1 or IMD2 partially or totally rescued MPA sensitivity of the transcription mutants, even those showing no defect in IMD2 and TPO1 expression (data not shown). We interpret this result as follows : suppression of MPA toxicity by overexpression of IMD2
or TPO1 is not strain specific but rather reflects the fact that the products of these genes contribute to Fig. 5C ). Interestingly, six of these mutants affect component of two protein complexes (pep3-pep5-vps33 and pep7-pep12-vps45) involved in transport from late Golgi to vacuole (37-38).
These mutants are also highly sensitive to aminoglycoside such as geneticin or hygromycin B although the reasons for this sensitivity are not yet clear (39-40). Why should these mutants be sensitive to MPA? One possibility could be that vacuolar function would be required for detoxification of MPA by TPO1 (see previous sections). Consistently, these vacuolar function mutants appear insensitive to 6AU
( Fig. 5C ) a drug which is not detoxified by overexpression of TPO1 (Fig. 1D ).
Three mutants, anp1, mnn10 and och1, affecting mannosyl transferase activity in the Golgi were sensitive to MPA (Fig. 6A ). Och1p is involved in initiation of α-1,6-polymannose addition (34) while Anp1p and Mnn10p belong to a complex involved in the α-1,6-polymerizing activity (35). We propose that these mutations could result in increased sensitivity to MPA as a consequence of underglycosylation which could affect cell wall integrity and enhance MPA uptake. Indeed, all three mutants are hypersensitive to other drugs such as hygromycin B (35, 36). Consistently, we found that addition of a sub-toxic dose of sodium dodecyl sulfate (SDS) which is highly toxic for the och1 mutant cells (36, Fig. 6B ), made wild-type cells hypersensitive to MPA (Fig. 6B) . This "synthetic" toxicity at very low doses of MPA and SDS in wild-type cells highlights the fact that MPA uptake is most probably notably limiting for its toxic effect.
Strikingly, two mutants affecting serine biosynthesis (ser1, ser2) and three affecting threonine biosynthesis (hom2, hom6, thr1) were sensitive to MPA. In both cases, MPA sensitivity could be relieved by specific addition of an excess of serine or threonine, respectively (Fig. 7) . These results suggest that serine and threonine uptake is impaired in the presence of MPA. Uptake of these aminoacids appears clearly limiting for growth, since addition of serine, competing with threonine for uptake, impairs growth of thr1 and hom2 mutants, while conversely, addition of threonine affects growth of the ser1 mutant (Fig. 7) . Consistently, two mutants affecting amino acid permeases, tat1 and bap2, are also highly sensitive to MPA suggesting that amino acid uptake is exquisitely sensitive to a decrease in guanylic nucleotide synthesis.
Finally, knock-out of several open reading frames (ORFs) of unknown function resulted in MPA sensitivity (Fig. 5D ). YDL100c encodes a putative protein similar to an efflux pump from E. coli and could be directly involved in MPA detoxification. YDR049w encodes a zinc finger containing protein expressed under stress conditions (heat shock, stationary phase...) and could therefore be a general stress response protein. Consistently, the ydr049 mutant is hypersensitive to rapamycin and cycloheximide (41). MPA sensitivity of mutants in such genes of unknown function provides a first clue to their function.
From this study, it clearly appears that all MPA sensitive mutants are not specifically affected in transcription elongation, although most transcription mutants identified behaved like previously described elongation mutants.
In such a global approach, an important issue is to determine the specificity of the mutants toward the drug of interest. Indeed, mutants affecting stress response or general drug detoxification processes are expected to lead to "unspecific" sensitivity to several drugs. Such mutants, while not very informative on the drug cellular effects, are helpful to understand how cells manage to detoxify the drug. To evaluate the specificity of the mutants identified in our screen, we compared our results to those obtained in a similar screen carried out on a partial knock-out library (2,216 yeast strains) with the immunosuppressive drug rapamycin (41). Mutations in 11 genes involved in transcription were found to affect rapamycin sensitivity, two of those mutants (rpb4 and spt8) were also found in our screen although these mutants are hypersensitive to MPA (this work) and hypo-sensitive to rapamycin (41). Therefore, MPA sensitivity of transcription mutants found in our screen does not result from a defect in a general cellular drug response. Furthermore, 6AU sensitivity of most MPA sensitive mutants
15/05/02
affecting transcription strongly argue for a specific dysfunction due to altered guanylic nucleotides synthesis. Nonetheless, several MPA sensitive mutants identified in this screen were also sensitive to rapamycin. These mutants affect various processes such as protein synthesis (rps27B), cell cycle and cytoskeleton (sic1, cik1, bem1, cdc10), metabolic pathways (hom2, ser1, ser2). Sensitivity of these mutants to both drugs could reflect their involvement, either in functions particularly vulnerable to drug disturbance or in pathways required for multiple drug resistance.
This genome-wide study revealed several cellular functions which are critical for natural resistance to MPA. Importantly, we found that most of the mutants affecting a specific function showed a similar sensitivity level. Indeed, we found for example that most of the highly sensitive mutants were transcription mutants while all the vacuolar mutants behaved similarly, being only slightly sensitive to the drug. Identification of MPA sensitive cellular functions should help to develop strategies to potentiate the effect of the drug and to limit its natural detoxification. 
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